FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	S IN BENEFICIAL	OWNERSHIP
_	_	=	_

OMB APPR	ROVAL
OMB Number:	3235-0287
Estimated average bu	rden
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Aviezer David				2. Issuer Name and Ticker or Trading Symbol Protalix BioTherapeutics, Inc. [PLX]									Relationship of eck all applications \mathbf{X} Directors	cable)	g Person	erson(s) to Issuer 10% Owner			
(Last) (First) (Middle) C/O PROTALIX BIOTHERAPEUTICS, INC. 2 SNUNIT STREET, SCIENCE PARK, POB 455				3. Date of Earliest Transaction (Month/Day/Year) 04/16/2009												Other (s _i below)	pecify		
(Street)	EL L3	3	20100		4. 1	If Ame	endme	ent, Date	of Origina	al Filed	i (Month/Da	ay/Yea	ar)	Line	X Form fi	iled by One	Reportin	ig Person	.
(City)	(S	•	(Zip)	n-Deri	vativ	- Sc	Curi	tios Ac	auirea	Dis	nnsad (of o	r Ben	eficial	ly Owned				
1. Title of Security (Instr. 3)		2. Trans	2. Transaction Date		2A. Deemed Execution Date,		3. Trans	3. Transaction Code (Instr.					5. Amou Securitie Benefici Owned F	nt of es ally following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)		
									v	Amount (A) or (D)		Price	Reported Transact (Instr. 3 a	ion(s)					
Common Stock			04/1	6/200	/2009		S		6,700	(1)	D \$2.5		c	0(2)			By Trust ⁽³⁾		
Common Stock			04/1	7/2009				S		10,000(1)		D	\$2.5	6 0	0(2)			By Γrust ⁽³⁾	
Common Stock			04/2	0/200	0/2009					33,300(1)		D	\$2.5	1 0	0(2)			By Frust ⁽³⁾	
Common Stock			04/2	0/2009				М		52,469		A	\$0.1	2 0(2)		I		By Γrust ⁽³⁾	
Common Stock 04/20/				0/200	/2009		F		2,469 D		D	\$2.5	0(2)		I		By Γrust ⁽³⁾		
		•	Table II -								osed of				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution D if any (Month/Day	Date,	4. Transa Code (8)		5. Number of		6. Date Expirati (Month/	on Dat		of S Und Deri	7. Title and A of Securities Underlying Derivative Se (Instr. 3 and 4		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactie (Instr. 4)	Owne Form: Direct or Ind (I) (Ins	vnership	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis		Expiration Date	Title		Amount or Number of Shares					
Stock Options (Right to Buy)	\$0.12	04/20/2009			M			52,469	(4)		12/08/2013		nmon ock	52,469	\$0	755,389	(5)	D	

Explanation of Responses:

- 1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- 2. The reporting person acquired 50,000 shares of common stock upon the exercise of outstanding options, all of which shares were sold by the reporting person.
- 3. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.
- 4. All of the options listed in Table II have vested.
- 5. Does not include options to purchase 977,296 shares of common stock at an exercise price equal to \$0.972 per share that expire on September 10, 2016, options to purchase 600,000 shares of common stock at an exercise price equal to \$5.00 per share that expire on February 7, 2018, and options to purchase 100,000 shares of common stock at an exercise price equal to \$2.65 that expire on February 25, 2019.

/s/ Yossi Maimon 04/20/2009

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.